Table 1.

Baseline patient characteristics (n = 103 patients totally)

Patient characteristics	Cutaneous melanoma		Mucosal melanoma		Melanoma of unknown primary
	N	%	N	%	N	%
No. patients, %	83	100	7	100	13	100
Age, years
Median (range)	63	(29–85)	63	(33–37)	62	(40–77)
Sex
Male	53	64	2	29	11	29
Female	30	36	5	71	2	71
ECOG baseline
0	51	61	2	29	12	92
1	23	28	5	71	1	8
2	9	11	–		–
BRAF mutation
Not mutated	29	35	3	43	5	39
Mutated	17	21	–		6	46
Not known	37	45	4	57	2	15
Disease stage (all: Stage IV)
M1a	6	7	–		3	23
M1b	15	18	2	29	1	8
M1c	62	75	5	71	9	69
LDH
<2 ULN	67	81	5	71	11	85
≥2 ULN	16	19	2	29	2	15
Brain metastases
No	57	69	5	71	10	77
Yes	26	31	2	29	3	23
Prior systemic therapy in stage IV (except radiotherapy)
No	–		–		–
Yes	83	100	7	100	13	100
Number of prior systemic therapies
1	42	51	6	86	8	62
2	27	33	–		3	23
≥3	13	16	1	14	2	15
Not applicable	1	1	–		–
Immunotherapy
No	67	81	7	100	11	85
Yes	16	19	–		2	15
If yes, type of previous immunotherapy
Interferon alpha	11	13	–		2	15
Vaccination	5	6	–		–
Kinase inhibitors
No	71	86	7	100	9	69
Yes	12	14	–		4	31
If yes, type of previous kinase inhibitor
BRAF inhibitor	7	8	–		2	15.5
MEK inhibitor	4	5			2	15.5
Chemotherapy
0	9	11	–		2	15
1	47	57	6	86	8	62
2	20	24	–		2	15
≥3	7	8	1	14	1	8

ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase